FDA Accepts BLA for Imsidolimab in Patients With Generalized Pustular Psoriasis The FDA has accepted a BLA for imsidolimab as a treatment for GPP, targeting December 12, 2026 for action.

The @fda.gov has accepted a Biologics License Application (#BLA) for #Imsidolimab as a treatment for generalized pustular psoriasis (#GPP), setting a target action date of December 12, 2026, according to a recent press release.

Read more: https://bit.ly/4ccJFnt

#RareDisease

Vanda Pharmaceuticals Celebrates FDA Acceptance for Imsidolimab in GPP Treatment Vanda Pharmaceuticals announces that the FDA has accepted its filing for Imsidolimab to treat Generalized Pustular Psoriasis. A potential breakthrough in dermatological therapies.

Vanda Pharmaceuticals Celebrates FDA Acceptance for Imsidolimab in GPP Treatment #USA #Washington #Vanda_Pharmaceuticals #Imsidolimab #Generalized_Pustular_Psoriasis

Vanda Pharmaceuticals Submits Biologics License Application for Imsidolimab to Treat Generalized Pustular Psoriasis Vanda Pharmaceuticals has submitted a Biologics License Application for Imsidolimab, a new treatment for Generalized Pustular Psoriasis, to the FDA.

Vanda Pharmaceuticals Submits Biologics License Application for Imsidolimab to Treat Generalized Pustular Psoriasis #United_States #FDA_Approval #Washington #Vanda_Pharmaceuticals #Imsidolimab

Vanda Pharmaceuticals and AnaptysBio Partner for Imsidolimab's Global Development in Psoriasis Treatment Vanda Pharmaceuticals and AnaptysBio have partnered to develop Imsidolimab, targeting Generalized Pustular Psoriasis, after successful Phase 3 trials.

Vanda Pharmaceuticals and AnaptysBio Partner for Imsidolimab's Global Development in Psoriasis Treatment #USA #Washington #Vanda_Pharmaceuticals #Imsidolimab #AnaptysBio